Nyxoah announces US Commercial Patients Implanted with Genio System

Early Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorisations, and Widespread Payor Coverage

Nyxoah SA, a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), announced that the first U.S. commercial patients have been successfully implanted with the Genio system following FDA approval.

"We are thrilled to announce that the first commercial patients have now received Genio implants, marking a significant milestone in bringing this innovative therapy to OSA patients in the U.S.," said Olivier Taelman, Chief Executive Officer. "Importantly, we have trained surgeons, obtained Value Analysis Committee (VAC) approvals and achieved successful coverage from major payors, including CMS. What's also particularly encouraging is the strong demand we're seeing from physicians, with surgeons actively reaching out for training opportunities, many of whom already have patients lined up for implants. These early leading indicators give us confidence that we're building the right foundation for the sustained adoption of Genio moving forward.”

Andrew T. Huang, MD FACS, Director of Sleep Surgery at Baylor College of Medicine, implanted the first Genio devices at Townsen Memorial Health System in Houston, TX. “I am excited to not only be the first surgeon to perform Genio implants commercially in the United States but to have completed my first five in one week. It was awesome to see the powerful and symmetric tongue protrusion at the end of each procedure. Like with any new procedure, there is a learning curve, but I’m excited to say the cases took me the same amount of time as my first unilateral HGN implants. The Genio system provides a solution for my patients who do not want two incisions, an implanted battery, and those where bilateral stimulation may be more beneficial to their airway anatomy,” commented Dr Huang. “Obstructive sleep apnea continues to represent a significant health burden in our country, and expanding access to new therapeutic options is essential. I am happy this therapy is now available in the US and am honoured to help improve access to Genio Therapy by offering it to my patients and helping to train more providers on this amazing procedure.”